Pathogenesis of triple-negative breast cancer
F Derakhshan, JS Reis-Filho - Annual Review of Pathology …, 2022 - annualreviews.org
Triple-negative breast cancer (TNBC) encompasses a heterogeneous group of
fundamentally different diseases with different histologic, genomic, and immunologic …
fundamentally different diseases with different histologic, genomic, and immunologic …
[HTML][HTML] ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
P Tarantino, G Viale, MF Press, X Hu… - Annals of …, 2023 - Elsevier
Human epidermal growth factor receptor 2 (HER2)-low breast cancer has recently emerged
as a targetable subset of breast tumors, based on the evidence from clinical trials of novel …
as a targetable subset of breast tumors, based on the evidence from clinical trials of novel …
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer
Background Among breast cancers without human epidermal growth factor receptor 2
(HER2) amplification, overexpression, or both, a large proportion express low levels of …
(HER2) amplification, overexpression, or both, a large proportion express low levels of …
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials
C Denkert, F Seither, A Schneeweiss, T Link… - The Lancet …, 2021 - thelancet.com
Background The development of anti-HER2 antibody–drug conjugates opens new
therapeutic options for patients with breast cancer, including patients with low expression of …
therapeutic options for patients with breast cancer, including patients with low expression of …
Human epidermal growth factor receptor 2 testing in breast cancer: ASCO–College of American Pathologists Guideline Update
AC Wolff, MR Somerfield, M Dowsett… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE To update ASCO–College of American Pathologists (CAP) recommendations for
human epidermal growth factor receptor 2 (HER2) testing in breast cancer. The Panel is …
human epidermal growth factor receptor 2 (HER2) testing in breast cancer. The Panel is …
Evolution of HER2-low expression from primary to recurrent breast cancer
F Miglietta, G Griguolo, M Bottosso, T Giarratano… - NPJ breast …, 2021 - nature.com
About a half of HER2-negative breast cancer (BC) show HER2-low expression that can be
targeted by new antibody-drug conjugates. The main aim of this study is to describe the …
targeted by new antibody-drug conjugates. The main aim of this study is to describe the …
[HTML][HTML] Evolution of low HER2 expression between early and advanced-stage breast cancer
Background Low human epidermal growth factor receptor 2 (HER2) expression is emerging
as an actionable biomarker for the treatment of breast cancer (BC) with novel anti-HER2 …
as an actionable biomarker for the treatment of breast cancer (BC) with novel anti-HER2 …
Clinicopathologic characteristics and prognosis of ERBB2-low breast cancer among patients in the National Cancer Database
Importance Given conflicting results regarding the prognosis of erb-b2 receptor tyrosine
kinase 2 (ERBB2; formerly HER2 or HER2/neu)–low breast cancer, a large-scale, nationally …
kinase 2 (ERBB2; formerly HER2 or HER2/neu)–low breast cancer, a large-scale, nationally …
Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status
G Zhang, C Ren, C Li, Y Wang, B Chen, L Wen, M Jia… - BMC medicine, 2022 - Springer
Background HER2-low breast cancers were reported to have distinct clinicopathological
characteristics from HER2-zero; however, the difference in their genetic features remains …
characteristics from HER2-zero; however, the difference in their genetic features remains …
HER2-low breast cancer: molecular characteristics and prognosis
E Agostinetto, M Rediti, D Fimereli, V Debien, M Piccart… - Cancers, 2021 - mdpi.com
Simple Summary The dichotomous classification of HER2 status is experiencing a paradigm
change, leading to the identification of the so-called “HER2-low” category. The aim of our …
change, leading to the identification of the so-called “HER2-low” category. The aim of our …